# A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

> **NCT05912296** · PHASE1 · COMPLETED · sponsor: **Suzhou Ribo Life Science Co. Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Hyperlipemia

## Interventions

- **DRUG:** RBD7022
- **DRUG:** RBD7022
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05912296
- **Lead sponsor:** Suzhou Ribo Life Science Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-30
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-03-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912296, "A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05912296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*